Revisiting dose-finding of monoclonal antibodies in migraine
暂无分享,去创建一个
[1] D. Hay,et al. CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond. , 2022, Physiological reviews.
[2] M. Weatherall,et al. Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis , 2022, Headache.
[3] S. Sacco,et al. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study , 2022, The Journal of Headache and Pain.
[4] M. Ferrari,et al. CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[5] P. Goadsby,et al. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions , 2022, The Lancet Neurology.
[6] R. Ruscheweyh,et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study , 2021, Cephalalgia : an international journal of headache.
[7] A. Maassenvandenbrink,et al. Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus , 2021, Frontiers in Neurology.
[8] E. Ludwig,et al. Relationship of the Calcitonin Gene‐Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin‐Induced Dermal Blood Flow in Healthy Subjects , 2021, Clinical pharmacology in drug development.
[9] A. Maassenvandenbrink,et al. Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications. , 2021, Maturitas.
[10] E. Loder,et al. Real-world effectiveness and tolerability of erenumab: A retrospective cohort study , 2020, Cephalalgia : an international journal of headache.
[11] K. Cahill,et al. Oral Candidiasis in a Migraine Patient Taking Erenumab and Galcanezumab: a Case Report , 2020, SN Comprehensive Clinical Medicine.
[12] W. Kielbasa,et al. Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine , 2019, Journal of clinical pharmacology.
[13] S. Sacco,et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? , 2019, The Journal of Headache and Pain.
[14] Edgar Bautista,et al. Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With Migraine , 2018, Clinical pharmacology and therapeutics.
[15] D. Grayzel,et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers , 2017, Front. Pharmacol..
[16] E. Lesaffre,et al. The influence of migraine and female hormones on capsaicin-induced dermal blood flow , 2017, Cephalalgia : an international journal of headache.
[17] T. Vu,et al. Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects , 2017, Pharmaceutical Research.
[18] T. Vu,et al. Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects , 2017, Pharmaceutical Research.
[19] J. Hoon,et al. Development of anti‐migraine therapeutics using the capsaicin‐induced dermal blood flow model , 2015, British journal of clinical pharmacology.
[20] S. Kushner,et al. Reduced trigeminovascular cyclicity in patients with menstrually related migraine , 2015, Neurology.
[21] K. Ibrahimi,et al. Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead , 2014, Cephalalgia : an international journal of headache.
[22] R. Lipton,et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS) , 2012, The Journal of Headache and Pain.
[23] B. Van der Schueren,et al. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. , 2007, British journal of clinical pharmacology.
[24] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..